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and compared to RNA populations purified from nonmi-
gratory follicle cells. The authors found 293 genes signif-
icantly enriched in border cells, 28% of which were also
regulated by slbo. These results were verified using RT-
PCR, RNA in situ hybridization, and immunostaining.
The border cell-enriched genes identified by Borghese
et al. correspond to a variety of functional groups,
most prominently general cytoskeletal regulators as
well as an intriguing group of genes heretofore consid-
ered ‘‘muscle-specific’’ (including rolling pebbles (rols),
a gene required for structural rearrangement of the cyto-
skeleton during myoblast fusion). Migrating border cells
might thus not only adjust their cell shape and adhesive-
ness, but also acquire ‘‘muscle-like’’ properties that al-
low them to actively invade the underlying tissue. The
authors further confirmed the significance of their ob-
tained gene expression profile for the migration of bor-
der cells in an exhaustive and thorough genetic exami-
nation. To this end, they assessed the rate of border
cell migration in mutants for a selection of genes from
different functional groups (including myosin heavy
chain, the microtubule regulator stathmin, rols, and the
transcription factors anterior open and vrille), demon-
strating their requirement for migration.
Both studies thus reveal how an elegant combination
of genetic and genomic approaches can be used to sig-
nificantly advance the molecular understanding of
a complex cellular process. The large number of border
cell-enriched and slbo-dependent genes identified is ex-
pected to guide efforts to understand how cell migration
is regulated and executed in vivo. The differing results of
the two studies do, however, also illustrate that genome-
wide expression profiles are never definitive descrip-
tions of a biological process. They will always constitute
mere snapshots of the dynamic physiology of cells. The
sheer number of parameters that affect cell function in
vivo clearly poses a significant experimental and con-
ceptual challenge. Our own journey to a complete de-
scription of even simple biological processes promises
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Hematopoietic Stem Cell Biology
Blood-forming hematopoietic stem cells (HSCs) en-
sure production of all mature blood cells during
homeostatic and regenerative hematopoiesis. Prolif-
eration, cell cycle regulation, and quiescence are key
processes involved in this function, and in a recent
issue of Cancer Cell, Lacorazza et al. (2006) show
that HSC quiescence is actively regulated by specific
molecular mechanisms that appear to distinguish nor-
mal HSC maintenance from HSC responses to hema-
tologic injury.
Analyses of genetically modified mice have been instru-
mental for our understanding of the roles of prolifera-
tion, cell cycle regulation, and quiescence in controllingstem cell numbers and functions. In the March issue of
Cancer Cell, Lacorazza et al. (2006) identify the Ets tran-
scription factor MEF/ELF4 as a novel component of the
transcriptional circuitry that actively and dynamically
regulates HSC proliferation and quiescence. Using an
impressive array of in vitro and in vivo assays, the au-
thors show that loss of MEF expression in MEF2/2
mice slows HSC proliferation in response to cytokine
stimulation and leads to an accumulation of mitotically
quiescent (G0-phase) HSCs in vivo. Enhanced HSC qui-
escence in MEF2/2 animals also increases HSC resis-
tance to cytoablative agents that target dividing cells,
and allows more rapid hematopoietic recovery after
chemoablative treatment. Interestingly, although MEF2/2
HSCs are more quiescent during homeostasic hemato-
poiesis, they display rapid proliferation after chemo-
therapy, implying that homeostatic and regenerative
HSC proliferation invoke distinct regulatory and mecha-
nistic pathways, a possibility previously hinted at by
gene expression analyses (Venezia et al., 2004; Pas-
segue´ et al., 2005).
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416Together, these findings suggest that MEF normally
functions to induce or facilitate the entry of quiescent
HSCs into the cell cycle and imply that MEF expression
and/or activity may be dynamically regulated in HSCs,
although this remains to be directly addressed. An
important next step will be to identify the intrinsic and
extrinsic regulators of MEF that normally antagonize
(or induce) its expression and/or function to limit (or pro-
mote) cell cycle entry in HSCs. To understand the mech-
anistic basis of MEF’s effects on HSC homeostasis, it
also will be essential to identify specific MEF target
genes in HSCs and to determine how MEF-mediated
control of HSC proliferation intersects with other re-
ported HSC-associated (e.g., p21, p18, ATM, GATA2,
Gfi-1, Bmi-1) and quiescence-associated (e.g., p130
Rb, cyclin C) regulatory pathways. Defining such regula-
tory networks also may have important implications for
understanding age-related changes in hematopoiesis,
as deregulation of factors such as MEF might contribute
to the enhanced proliferation (and decreased function)
seen in aging HSCs (Morrison et al., 1996).
A curious finding of the Lacorazza study is the some-
what paradoxical accumulation of quiescent HSCs in
the bone marrow of MEF2/2 mice under steady-state
conditions, which occurs without any apparent alter-
ation in the production of mature, circulating blood
cells. This property appears to be HSC intrinsic, as qui-
escent MEF2/2 HSCs also accumulate in the bone mar-
row of wild-type mice transplanted with MEF-deficient
cells. Previous studies have implicated signals emanat-
ing from the HSC ‘‘niche’’ in maintaining HSC quies-
cence (Arai et al., 2004), and so, these findings may sug-
gest that MEF downregulation is one target of such
microenvironmental signals. The accumulation of G0
MEF2/2 HSCs in the bone marrow could be explained
by increased retention of these cells or by changes in
their survival or self-renewal properties, although,
based on assays employing cytokine-induced mobiliza-
tion and serial bone marrow transplantation, the authors
dismiss these possibilities and instead favor the hy-
pothesis that inactivation of MEF slows the rate of
HSC maturation into more committed progenitor cells,
thereby allowing persistence of ‘‘stemness’’ in vitro
and homeostatic accumulation of HSCs in vivo. Yet, be-
cause both mobilization and transplantation assays
may invoke a ‘‘regenerative’’ proliferation response
from HSCs, which the authors show to be refractory to
loss of MEF activity, it seems that such alternative
explanations may merit further consideration. Future
investigations of MEF2/2 HSCs that directly measure
the kinetics of G0 transit and analyze in detail the molec-
ular regulators of G0-to-G1 transition will help to more
clearly delineate the reasons why these cells accumu-
late in the bone marrow.
Although many biological questions remain to be
addressed, the demonstration by Lacorazza and col-
leagues that HSC quiescence is an actively and dy-
namically controlled state that can be manipulated by
particular transcriptional regulators suggests exciting
possibilities for biomedical applications. As the authors
demonstrate that acute reduction of MEF expression,
by as little as 30%, enhances quiescence in hematopoi-
etic progenitor cells, one may speculate that MEF inhibi-
tion could be exploited clinically to hold HSCs in quies-cence during chemotherapy, and thereby protect them
from cytotoxic injury. In addition, induced downregula-
tion of MEF in HSCs prior to transplantation might be
useful to enhance engraftment efficiency, as quiescent
HSCs appear much more effective than cycling HSCs
at providing long-term, multilineage hematopoietic re-
constitution (Glimm et al., 2000; Passegue´ et al., 2005).
Such a strategy could be particularly useful for trans-
plantation of recently divided HSCs, such as those de-
rived from mobilized peripheral blood or from ex vivo
expanded HSC cultures, in order to reestablish quies-
cence in these cells prior transplantation. Indeed,
such applications garner support from the Lacorazza
et al. study, which also shows that MEF2/2 HSCs out-
compete wild-type HSCs upon serial transplantation
to secondary recipient mice. Because the serial trans-
plants were done 2 months after primary transplanta-
tion, a time at which wild-type HSCs are still in a state
of enhanced proliferation (Allsopp et al., 2001), it is likely
that differences in proliferative status explain why, with
equivalent engraftment in primary recipients, the more
quiescent MEF2/2 HSCs are favored in secondary
transplants.
For all these potential biomedical applications, a sig-
nificant challenge will be to specifically target MEF ac-
tivity in the appropriate cell population, e.g., the HSCs.
Such targeting is also important when considering the
implications of this study for leukemia and leukemic
stem cells (LSCs), the rare population of cells proposed
to maintain these blood cell cancers. The majority of
therapies currently used for leukemia treatment have
been designed based on the highly proliferative proper-
ties of malignant blasts; however, all human LSCs iden-
tified so far appear to be largely quiescent, and thus
may be refractory to conventional treatments (reviewed
in Jordan and Guzman, 2004). Given the importance of
LSCs for disease propagation, effective therapies for
human leukemias must specifically ablate these cells,
and it is tempting to speculate that induction of MEF ex-
pression in LSCs could lead to their recruitment into cell
cycle and sensitize them to chemotherapy. With this in
mind, it will be essential to determine whether MEF ex-
pression is actually perturbed in LSCs (or other cancer
stem cells), and whether this is indeed a mechanism
that promotes LSC insensitivity to chemoablation.
In summary, the study by Lacorazza and colleagues
clearly indicates the importance of cell cycle regulation
in the biologic function of adult blood-forming stem
cells, and supports earlier studies implicating distinct
cell cycle regulators in the control of HSC number (re-
viewed in Cheng, 2004). Whether MEF itself, or similar
transcriptional regulators of stem cell proliferation,
functions to actively determine the balance between
proliferation and quiescence in other stem cell popula-
tions remains an important outstanding question. In-
triguingly, relative quiescence appears to be a common,
and perhaps essential, property of many adult somatic
stem cell populations identified to date, including hema-
topoietic stem cells, epidermal and melanocyte stem
cells, neural stem cells, and myogenic satellite cells (re-
viewed in Cheng, 2004; Dhawan and Rando, 2005). The
biological rationale behind this relative quiescence of
adult stem cells remains incompletely defined, although
it may serve to prevent their premature exhaustion
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417in vivo or to minimize their accumulation of replication-
associated mutations. Significantly, studies such as this
one that begin to uncover the molecular underpinnings
of quiescence regulation provide a mechanistic foot-
hold from which to further dissect this key stem cell
property.
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